All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2023-10-24T07:49:18.000Z

What are the management considerations for accelerated- and blast-phase MPN?

Oct 24, 2023
Share:
Learning objective: After reading this, learners will be able to cite a new clinical development in accelerated- and blast-phase MPN.

Bookmark this article

During the 2023 Society of Hematologic Oncology (SOHO) annual congress, the MPN Hub was pleased to speak to Olatoyosi Sobulo Odenike, University of Chicago, Chicago, US. We asked, what are the management considerations for accelerated- and blast-phase MPN?

What are the management considerations for accelerated- and blast-phase MPN?

In the interview, Odenike outlines the characteristics of accelerated- and blast-phase MPN and highlights important management considerations, including key diagnostic and cytogenetic tests. Odenike concludes by discussing treatment goals and the increasing importance of clinical trials for this patient population.

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox